Testing the combination of two approved drugs and one experimental drug in patients with multiple myeloma that do not respond to the drug known as lenalidomide and proteasome inhibitor-based therapy

What we are studying

The purpose of this study is to compare the effects, good and/or bad, of the study drugs pomalidomide, ixazomib and dexamethasone, or the study drugs pomalidomide and dexamethasone, on you and your multiple myeloma to find out which is better. In this study, you will get either the study drugs pomalidomide, ixazomib and dexamethasone or the study drugs pomalidomide and dexamethasone. If you are assigned to the study drugs pomalidomide and dexamethasone and experience progression of your multiple myeloma, you will have the option to receive the study drug ixazomib in combination with the study drugs pomalidomide and dexamethasone.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 80

Eligibility Criteria

  • Multiple myeloma not responsive to prior treatments

What is involved

  • Study participants will be randomized to receive pomalidomide
  • Dexamethasone and ixazomib or pomalidomide and dexamethasone

Compensation

Parking validation for all study related visits

Contact Information

Study Coordinator
Suzanne Carroll
Email
scarroll@wakehealth.edu
Phone
336-713-5719

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.